Patent ID: 7919671

Claim:
A method of screening for a compound that decreases PI(4,5)P 2 accumulation or decreases PI(3)P levels comprising: (a) administering said compound to a knockout mouse whose genome comprises a homozygous disruption in a nucleic acid encoding prostatic acid phosphatase (PAP), wherein said disruption results in the null inactivation of PAP and wherein said knockout mouse exhibits prostatic atypical hyperplasia, prostatic intraepithelial neoplasia, adenocarcinoma of the prostate, myopathy or neuropathy; and (b) determining if said administered compound decreases PI(4,5)P 2 accumulation or decreases PI(3)P levels compared to PI(4,5)P 2 accumulation or PI(3)P levels in a knockout mouse whose genome comprises a homozygous disruption in a nucleic acid encoding PAP, wherein said disruption results in the null inactivation of PAP not administered said compound; wherein said decreased PI(4,5)P 2 accumulation or said decreased PI(3)P level indicates that said compound is a candidate therapeutic for treating disorders related to increased PI(4,5)P 2 accumulation or increased PI(3)P levels.